TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors

ABSTRACT: The purpose of this study is to evaluate the safety and tolerability of orally administered TT-4 in subjects with advanced selected solid tumors. The dose escalation portion of the study will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of TT-4.

DISEASE(S): Gastric Cancer,Colorectal Cancer,Pancreatic Cancer,Hepatocellular Carcinoma

PROVIDER: 2384438 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR